ArticleHormones (Athens, Greece)2026
Fatty liver and diabetes are related to benign prostate hyperplasia.
Article in Hormones (Athens, Greece), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough prior studies have suggested an association between benign prostatic hyperplasia (BPH) and metabolic abnormalities, many were limited by small sample sizes. The study aimed to identify metabolic risk factors related to BPH.
methodsFollowing rigorous screening, 8,566 men aged 40 years or older were enrolled in 2022 in the current research. All participants underwent prostate and liver ultrasonography.
resultsThe mean age of the subjects was 54.20 ± 9.37 years, Among them, 3,595 (41.96%) were diagnosed with BPH and 5519 (64.42%) had fatty liver disease (FLD), while 1,254 (14.63%) had diabetes. Multivariate analysis revealed that four variables, namely, age, prostate special antigen (PSA), FLD, and diabetes were related to BPH. Specifically, each 1-year increase in age was associated with an 8% increase in BPH risk (odds ratio [OR], 1.08; 95% confidence interval [CI], 1.07-1.09). Elevated PSA was associated with a 91% increase in BPH risk (OR, 1.91; 95% CI, 1.79-2.04). The presence of FLD was linked to a 21% increased risk (OR, 1.21; 95% CI, 1.08-1.36), and diabetes was correlated with a 22% increased risk (OR, 1.22; 95% CI, 1.06-1.40).
conclusionAdvanced age, elevated PSA levels, and the presence of FLD and/or diabetes are associated with an increased risk of BPH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.